In the latest market close, Biogen Inc. (BIIB) reached $227.36, with a -1.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 1.12%. Meanwhile, the Dow experienced a rise of 0.61%, and the technology-dominated Nasdaq saw an increase of 1.54%.The company's stock has dropped by 5.99% in the past month, falling short of the Medical sector's gain of 2.49% and the S&P 500's gain of 2.06%.Investors will be eagerly watching for the performance of Biogen Inc. in its upcoming earn ...

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most participants treated with SPINRAZA after gene therapy CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label R ...

New data advances understanding of new approaches to treating Alzheimer's diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced it will present new data from its Alzheimer's disease (AD) portfolio at the upcoming International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place March 5-9 in Lisbon, Portugal and virtually. The presentations include new data for its ora ...

If you’re looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ:IBB) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.  But that exchange traded fund (ETF) hasn’t done well in recent years. In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably less than the 8.74% for the SPDR S&P 500 ETF Trust (NYSEARCA:SP ...

Biogen Inc. (NASDAQ:BIIB) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Head of North America Priya Singhal - Head of Development and Interim Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen Michael McDonnell [Call Starts Abruptly] So good morning and thank you very much to everyone for being with us today. I would say that the launch of LEQEMBI is going in line ...

Biogen Inc. (NASDAQ:BIIB) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Head of North America Priya Singhal - Head of Development and Interim Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen Michael McDonnell [Call Starts Abruptly] So good morning and thank you very much to everyone for being with us today. I would say that the launch of LEQEMBI is going in line ...

On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (BIIB 1.82%) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newly launched drug called Leqembi, which aims to treat Alzheimer's disease. But Leqembi is just one of four recent launches, with the other medicines treating conditions like postpartum depression and amyotrophic lateral sclerosis (ALS).Schmidt is likely to ...

Company Performance - Biogen Inc. (BIIB) ended the latest trading session at $221.74, reflecting a -0.98% change from the previous close, which is less than the S&P 500's daily loss of 0.17% [1] - Over the past month, Biogen's shares have decreased by 9.37%, while the Medical sector gained 5.93% and the S&P 500 gained 3.98% [1] - The upcoming earnings report is expected to show an EPS of $3.47, a 2.06% increase from the prior-year quarter, with revenue estimated at $2.32 billion, indicating a 5.67% decrease year-over-year [1] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict earnings of $15.48 per share and revenue of $9.45 billion, reflecting changes of +5.16% and -3.91% from the previous year, respectively [2] - Recent modifications to analyst estimates for Biogen indicate evolving short-term business trends, with positive revisions suggesting a favorable outlook on the company's health and profitability [2] Valuation Metrics - Biogen currently has a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 1.51% in the past month [3] - The company is trading at a Forward P/E ratio of 14.46, which is a discount compared to the industry's average Forward P/E of 22.45 [3] - Biogen's PEG ratio stands at 1.87, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.51 [3] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 85 [4] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks within these groups [4]

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommend ...

Revenue and Product Performance - TECFIDERA, TYSABRI, and SPINRAZA each accounted for over 10.0% of total revenue for the years ended December 31, 2023, 2022, and 2021[48]. - Two wholesale distributors accounted for over 10.0% of total revenue, combined accounting for approximately 36.9%, 37.9%, and 38.9% of gross product revenue for the years ended December 31, 2023, 2022, and 2021, respectively[70]. - TECFIDERA's revenue has been significantly reduced due to generic competition, and future revenue is expected to continue declining[89]. - The commercialization of competing products, such as ZOLGENSMA and EVRYSDI, is anticipated to adversely affect sales of SPINRAZA in the spinal muscular atrophy market[92]. - LEQEMBI and SKYCLARYS are in the early stages of commercial launch in the U.S., with potential revenue impacted by reimbursement challenges and competition[185]. Collaborations and Acquisitions - The company terminated its collaboration and license agreement with Neurimmune for ADUHELM in November 2023[52]. - The acquisition of Reata in September 2023 included SKYCLARYS for Friedreich's ataxia (FA)[55]. - The collaboration with Eisai for LEQEMBI involves equal sharing of costs and profits, with a ten-year supply agreement for manufacturing[102]. - The company has a global collaboration with Sage Therapeutics for zuranolone, sharing development costs and profits in the U.S., with potential tiered royalties outside the U.S.[103]. - The company has entered into a collaboration with Denali to co-develop small molecule inhibitors for Parkinson's disease, sharing development costs and profits in the U.S. and China[107]. Intellectual Property and Regulatory Matters - The company regularly seeks patent protection for inventions from its research and development efforts[71]. - The patent portfolio includes key patents for marketed products, with expected expiration dates ranging from 2024 to 2035, ensuring continued market exclusivity[74]. - TECFIDERA's patent in Europe is set to expire in 2024, while its regulatory exclusivity is expected until 2025[81]. - The company continues to pursue additional patents and extensions to enhance product exclusivity beyond current expirations[74]. - Regulatory data protection and market protection are critical for maintaining competitive advantage in the pharmaceutical market[73]. Competition and Market Challenges - The introduction of generic versions and biosimilars in the multiple sclerosis (MS) market is expected to significantly reduce the price and volume of existing products, negatively impacting revenue[87]. - The company faces intense competition in the biopharmaceutical industry, with competitors having greater financial and technological resources[86]. - Biosimilar competition for RITUXAN has led to a substantial decrease in sales and profits from collaboration arrangements with Genentech[94]. - The company is aware of other products in development that may compete with its existing products, which could further impact future sales[92]. - The company’s ability to maintain pricing and market share is threatened by the introduction of new products and generics, which could lead to reduced revenue[192]. Financial Performance and Investments - Working capital decreased to $3.4 billion as of December 31, 2023, from $6.5 billion a year earlier, reflecting a decrease in total current assets by approximately $2,931.9 million and an increase in total current liabilities by approximately $161.5 million[351]. - Cash, cash equivalents, and current marketable securities decreased by $3,842.9 million primarily due to the acquisition of Reata and early repayment of $350.0 million in debt obligations related to this acquisition[352]. - Net cash flow provided by operating activities increased by 11.8% to $1,547.2 million in 2023 compared to $1,384.3 million in 2022[357]. - Long-term debt outstanding was $6,788.2 million as of December 31, 2023, including $650.0 million under the 2023 Term Loan[362]. - The company repurchased approximately 3.6 million shares at a cost of $750.0 million under its share repurchase program in 2022, with $2.1 billion remaining available as of December 31, 2023[364]. Regulatory Compliance and Risks - The company is subject to stringent FDA regulations regarding product approval and changes, which may require additional clinical trials and significant expenditures[116]. - The company is subject to civil monetary penalties if it fails to provide timely information or submits false information regarding Medicaid and Medicare pricing[129]. - The company faces significant risks related to compliance with international laws and regulations, which may vary significantly across different markets[213]. - The company is subject to extensive government regulation, and violations could result in criminal and civil sanctions, including fines and exclusion from government programs[212]. - The company may incur substantial costs related to compliance with evolving legal and regulatory requirements in the healthcare industry, which could impact its business practices[209]. Corporate Governance and Workforce - As of December 31, 2023, the company had approximately 7,570 employees worldwide, with 4,140 in the U.S. and 3,430 in foreign countries[152]. - 31.2% of manager-level and above positions in the U.S. were held by ethnic or racial minorities, while 48.6% of director-level and above positions globally were held by women[153]. - The company has integrated ESG oversight into its Board of Directors' governance principles, with a focus on advancing ESG efforts tied to employee compensation[147]. - The company has conducted a talent review to manage succession plans for critical roles, ensuring long-term continuity of the business[159]. - The company has refreshed its flexible working arrangement policies to better support employees' work-life balance[158]. Management and Leadership - Mr. Viehbacher has been the President and CEO of Biogen since November 2022, previously serving as Managing Partner at Gurnet Point Capital and Global CEO of Sanofi[169]. - Ms. Alexander has been the Chief Legal Officer since April 2018, with prior roles including Executive Vice President of Legal and Corporate Services[170]. - Mr. McDonnell has served as CFO since August 2020, previously holding CFO positions at IQVIA and Intelsat[172]. - Ms. Murphy has been the Executive Vice President of Pharmaceutical Operations and Technology since February 2022, previously leading Global Manufacturing & Technical Operations[173]. - Dr. Singhal has been the Executive Vice President and Head of Development since January 2023, with a history at Biogen and Vertex Pharmaceuticals[177].